ValVention, Inc. was founded with the mission to mitigate structural heart disease through innovative medical technologies. The company focuses on developing next-generation transcatheter heart valves and minimally invasive cardiac support technologies. Their primary products include the FoldaValve™ and Helix Cardia™, which are designed to address valvular heart disease and reduce the burden of heart failure. ValVention aims to meet significant unmet clinical needs in the cardiovascular market.
Notable affiliated individuals and investors include key figures from the medical device industry and venture capital firms specializing in healthcare innovation. One of ValVention's key achievements is receiving a $350,000 grant from the National Institutes of Health (NIH) to validate their new heart valve replacement system. The company's impact is marked by its potential to significantly improve patient outcomes in structural heart disease, positioning it as a leader in cardiac innovation.
